NDAORALTABLETPriority Review
Approved
Jun 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Phenurone (phenacemide) is an oral tablet small molecule approved in 1951 as an anticonvulsant. The drug's exact mechanism of action and current clinical indications are not fully documented in available data, reflecting its legacy status as a mid-20th century therapeutic. It represents a historical example of early synthetic pharmaceutical development.
LOE Approaching
This legacy product is approaching loss of exclusivity with minimal commercial infrastructure, indicating limited career growth potential and likely team contraction or consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Phenurone offers limited career trajectory; this is a sunset product managed for compliance and residual revenue rather than growth. Career value lies in regulatory stewardship or niche sales expertise rather than strategic advancement.
Brand Manager (maintenance)Field Sales Representative
Worked on PHENURONE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.